SCHEMBL6025614

SCHEMBL6025614

O=C(c1ncc(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2Cl)n1)N1CCC(N2CCCCC2)CC1

nearest known ligand 0.58

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 15/20 0.58
ACKR3 P25106 1/20 0.44
CNR2 P34972 3/20 0.44
LRRK2 Q5S007 1/20 0.44
HRH3 Q9Y5N1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6807596 0.90 CNR1 (0.71) CNR1CNR2
SCHEMBL6025823 0.88 CNR1 (0.56) CNR1CNR2
SCHEMBL6025602 0.85 CNR1 (0.53) CNR1CNR2
SCHEMBL6025222 0.84 CNR1 (0.52) CNR1CNR2
SCHEMBL6808103 0.83 CNR1 (0.51) CNR1CNR2
SCHEMBL6025806 0.83 CNR1 (0.56) CNR1CNR2
SCHEMBL6025648 0.82 CNR1 (0.56) CNR1CNR2HRH3
SCHEMBL6026092 0.82 CNR1 (0.56) CNR1
SCHEMBL6025796 0.81 CNR1 (0.58) CNR1CNR2
SCHEMBL6026396 0.80 ALPL (0.54) CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040259887-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-12-23 US claimed
EP-1638570-A1 PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS Pfizer Products Inc. (US) 2006-03-29 EP disclosed
US-20040259887-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-12-23 US disclosed
WO-2004110453-A1 PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS PFIZER PRODUCTS INC. (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259887-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 CNR1 1/4885ACKR3 582/4885CNR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.